Aclaris Therapeutics

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More
Ocugen

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a Pennsylvania-based biopharmaceutical company, has scored a significant regulatory milestone this week with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine …

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment Read More


Cantaloupe

Cantaloupe, Inc. and Canteen of Northern California Forge a Groundbreaking Partnership to Integrate Innovative Vending Technology

MALVERN, PA — Cantaloupe, Inc. (NASDAQ: CTLP), a leading provider of innovative vending and micro market technology, has successfully onboarded Canteen of Northern California (CNC). This partnership marks a major …

Cantaloupe, Inc. and Canteen of Northern California Forge a Groundbreaking Partnership to Integrate Innovative Vending Technology Read More
Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics provider, has shared promising top-line results from the Phase 3 trial of TO-208 for molluscum contagiosum (“molluscum”) …

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan Read More